Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country

Giannina IzquierdoJuan Pablo TorresMarı́a Elena SantolayaMaría Teresa ValenzuelaJeannette VegaMay Chomalí2026-03-222026-03-22201510.1080/21645515.2015.1010885https://doi.org/10.1080/21645515.2015.1010885https://andeanlibrary.org/handle/123456789/48487Citaciones: 15Implementation of a mass vaccination campaign to control a hypothetical NmenB outbreak in Chile would be cost-effective at a vaccine cost per dose ≤ of USD$18. This is the first report of a cost-effectiveness analysis for use of 4CMenB as a single intervention strategy to control an epidemic outbreak of NmenB.enMedicineOutbreakVaccinationContext (archaeology)Meningococcal diseaseEnvironmental healthPopulationMass vaccinationIncidence (geometry)Cost analysisCost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income countryarticle